drugset

drugset / Trial / NCT00346827

Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.

NCT00346827 ↗

Phase 2/3 Completed 36 enrolled Britannia Pharmaceuticals Ltd.

SequentialDouble-blindTreatment

Summary

To determine the safety and tolerability of repeated dosing with Apomorphine Nasal Powder in subjects with Parkinson's Disease.

Timeline

Start: 2006-07
Primary completion: 2007-08
Completion: 2007-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Apomorphine	Unknown	—	—

Indications